We are live on ! Find out more
LCM

Lynx1 Capital Management Portfolio holdings

AUM $633M
1-Year Est. Return 173.22%
This Fund
S&P 500
This Quarter Est. Return
-5.46%
1 Year Est. Return
+173.22%
3 Year Est. Return
+779.42%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$111M
AUM Growth
-$6.52M
Cap. Flow
+$3.16M
Cap. Flow %
2.85%
Top 10 Hldgs %
96.74%
Holding
12
New
–
Increased
6
Reduced
4
Closed
–

Top Buys

Rank Stock Value
1
ALPN
Alpine Immune Sciences Inc
ALPN
+$9.31M
2
PASG icon
Passage Bio
PASG
+$4.59M
3
OTIC
Otonomy, Inc.
OTIC
+$2M
4
JBIO
Jade Biosciences
JBIO
+$1.62M
5
PVLA
Palvella Therapeutics
PVLA
+$470K

Top Sells

Rank Stock Value
1
MRUS
Merus
MRUS
+$9.26M
2
BLU
BELLUS Health Inc.
BLU
+$4.78M
3
CBAY
Cymabay Therapeutics
CBAY
+$948K
4
IMUX icon
Immunic
IMUX
+$134K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BLU
1
DELISTED
BELLUS Health Inc.
BLU
$25.2M 22.69%
2,382,127
-449,461
-16% -$4.78M
ALPN
2
DELISTED
Alpine Immune Sciences Inc
ALPN
$22M 19.85%
3,056,420
+1,129,551
+59% +$9.31M
KNTE
3
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$20M 18.05%
1,674,677
– –
MRUS
4
DELISTED
Merus
MRUS
$12.3M 11.08%
613,071
-388,146
-39% -$9.26M
CBAY
5
DELISTED
Cymabay Therapeutics
CBAY
$8.14M 7.34%
2,325,833
-263,846
-10% -$948K
JBIO
6
Jade Biosciences
JBIO
$1.22B
$4.58M 4.13%
7,898
+2,425
+44% +$1.62M
PRDS
7
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$4.21M 3.8%
2,275,732
+95,172
+4% +$284K
PVLA
8
Palvella Therapeutics
PVLA
$1.98B
$4.04M 3.65%
43,939
+3,647
+9% +$470K
PASG icon
9
Passage Bio
PASG
$15.9M
$3.44M 3.1%
137,621
+116,550
+553% +$4.59M
IMUX icon
10
Immunic
IMUX
$182M
$3.39M 3.06%
107,229
-3,195
-3% -$134K
THRX
11
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$2.93M 2.64%
504,862
– –
OTIC
12
DELISTED
Otonomy, Inc.
OTIC
$682K 0.62%
2,312,880
+2,282,880
+7,610% +$2M

Similar funds

SWM
SilverOak Wealth Management Edina, Minnesota $632M AUM 18.6% 1-Year Est. Return
RFA
Rollins Financial Advisors New York City, New York $632M AUM 23.84% 1-Year Est. Return
WA
WFM Asia Road Town, Tortola, British Virgin Islands $632M AUM 14.51% 1-Year Est. Return
AMM
American Money Management Rancho Santa Fe, California $632M AUM 14.06% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
ACM
Arini Captial Management London, United Kingdom $634M AUM
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return

Lynx1 Capital Management's Q3 2022 Portfolio in Review

As of Q3 2022, Lynx1 Capital Management held 12 positions worth $111M, down 5.6% from $117M the previous quarter. Its ten largest holdings account for 97% of the portfolio.

Trading was light in Q3 2022: portfolio turnover was 0%. Lynx1 Capital Management opened no new positions and made no exits, leaving the 12-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Lynx1 Capital Management added most to Alpine Immune Sciences Inc in Q3 2022, an estimated $9.31M increase.
  • Lynx1 Capital Management's biggest Q3 2022 reduction was Merus, cutting an estimated $9.26M.
  • Lynx1 Capital Management's ten largest holdings make up 97% of its $111M portfolio in Q3 2022.
  • Lynx1 Capital Management opened 0 new positions and closed 0 in Q3 2022.
  • Lynx1 Capital Management's portfolio value fell 5.6% quarter-over-quarter to $111M.

Based on Lynx1 Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.